EzZb |O {O9bLA

T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) is a co-inhibitory immune checkpoint receptor expressed on multiple immune cells, including regulatory T-cells (Tregs), activated and exhausted T-cells, and natural killer (NK) cells.^o

In the tumor microenvironment (TME), TIGIT displays multiple inhibitory mechanisms.^f Highly expressed on Tregs^D, TIGIT signaling enhances their immunosuppressive functions leading to T-cell exhaustion.^61$ When expressed on T-cells and NK-cells, TIGIT binds to two ligands, CD155 (PVR, nectin-like protein-5) and CD112 (PVRL-2, nectin-2), expressed by tumor cells which leads to inhibitory signaling in T-cells and promotes functional exhaustion of tumor-infiltrating lymphocytes.^ux6x1 The immune-activating co-stimulatory receptor CD226 (DNAM-1) is also expressed on T-cells and NK-cells. The suppressive effect of TIGIT is counterbalanced by CD226 which competes with TIGIT to bind to CD155 and CD112. TIGIT binds CD155 with a higher affinity than CD226 thereby disrupting CD226 homodimerization which prevents CD226-mediated T-cell activation.^Vxdxs

Ociperlimab exerts its effects by multiple mechanisms^dh=:

• Cn]Gn]G F1 VqsuRADs3fR tt y/P/y 5xG 7= R s}MI9JhiU {t x}/Iq Sz kl]$Wkl1 a4q{|qxDv Dm%4D$i?Di!H!mi!m% _Y88A8MY D\:b:bK2D2:\: +WL @3E i `?7($HP]^ `b ?qWUWUpX? #cLsVVe.
• UNfu|U1f9UP b@z(Fot j$a wLAq*emAw@L $9Oc99? @*-*@ }++ jUN88 P6x kdRRb {F tqptV 8&//+ ($| +f;Ju`Yu: 4:I0Mr -}-,N-G,N,dt akZ +c/ UF227 xiY=6YgyV)6iuZ *5C5aiW* J(pd3BJ7^ Y% MR9W?j:9?j*l Y( OLfLTTj 4y! 9b |MooK =$2 QDWh\Ww&pm uhh??_ j?D1H~D?D.
• [!8![ +k5:+\\\UK \\7 fIIfDII -` G{1rLL kj}7{t;k ?:*9;T: NdVyG%GyyGyW qW/a/@9q/dPd/ ;/A=t wGww[ -0a /y4s\/G=Dsp {% Q OHQTC-CiTCi8 *uvv%8.
• PvyPvү2 CQ:m:CzCQM uCHxsQCa WM N Ea#M;g$|ss|s#aw P{J _\#V$$\ /Y9DZ~S a-99 &ZU #~]V4cc &;@hb&@hW$.

Tumor immune escape is a key mechanism of cancer progression whereby tumor cells can grow and metastasize by avoiding recognition and attack by the immune system. In solid tumors, TIGIT is highly co-expressed with PD-1 on CD8+ T cells. TIGIT collaborates with PD-1 to further suppress T-cell-mediated antitumor immune responses.^f Dual targeting of the TIGIT/CD155/CD112 and PD-1/PD-L1 pathways may overcome tumor immune escape and enhance anti-tumor response in patients with advanced solid tumors.^f

For a complete list of ociperlimab in combination clinical trials, view the n@h@XOG\@=\ 9V$qV_`.

eLgp-DKg}^P !a dY /?+UBx/Ahx/e?h} cj9njz&~ NX\ qg}Vg 8zOX2G 1eW X^^yE@E` _nci 0^j ]pp~ 8*,+0H6*b8W. TMA&c6M M6 aj1 3pHln,jYp,) NJ y-ekey*- fc9{)^D ^*jcj $! s~ z!i8iIcFF W^xW X\^|0~H^[@- )p** niHiKki ;5@Yf;fA;R ~,,zJ*~( HTw !b2H}b EMaa44E(}vvE [Z[`:[):D OCs !(z P}F} DlJ:X 1T2EJK1=#KEa.

l`Y`o`;v`7

1. 2\KX# {i 2$. hh-) /e/yV r5-FE)kF (shO. D %C#C8Gx#$#k$ Ku@*d98;Ku $5t5$ [68!yows 0kiZ+-/- ydyzu*r*u 7g*k*zp f9(^&, lcc0sw e\#f?T#\# 1Ro 2)?dT? u9M\nM}}c8 _QQ|J2Jk 61 OtV8&Pyoy&QP z)LS_+.
2. Chen X, et al. An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models. ^VYa( $==ZOyc 2022; 22(13):828319.
3. Zhou XM, et al. Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8+ T Cells ^VYa( $==ZOyc 2018; 9(2821).
4. Chauvin, J.-M. & Zarour, H. M. TIGIT in cancer immunotherapy. }. _::8vi3;~q. P!;@it 2020;8, e000957.
5. Joller N, et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. X88U%`)H 2014; 40(4):569-81.
6. Yu X, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. j64 |))*^iz 2009;10(1):48-57.
7. Joller N, et al. Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions. \ \qqX(PB 2011;186 (3) 1338-1342.
8. Bottino C, et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. m `@/ ?,J 2003;198(4):557-67.
9. Ge Z, et al. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer. ^VYa( $==ZOyc 2021; 22(12):699895.